Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.

Abstract

INTRODUCTION:

Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively. Splitting the first intravenous infusion of daratumumab over 2 days is an approved alternative dosing regimen to reduce the duration of the first infusion and provide flexibility for patients and healthcare providers.

METHODS:

The feasibility of splitting the first 16-mg/kg infusion into two separate infusions of 8 mg/kg on Days 1 and 2 of the first treatment cycle was investigated in two cohorts [daratumumab, carfilzomib, and dexamethasone (D-Kd) and daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)] of the phase 1b MMY1001 study. Additionally, a population pharmacokinetic (PK) analysis and simulations were used to compare the PK profiles of the split first dose regimen with the recommended single first dose regimens of daratumumab in previously approved indications.

RESULTS:

In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml]. At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml]. The population PK simulations demonstrated virtually identical PK profiles after the first day of treatment for all approved indications and recommended dosing schedules of daratumumab.

CONCLUSION:

These data support the use of an alternative split first dose regimen of intravenous daratumumab for the treatment of MM.

TRIAL REGISTRATION:

ClinicalTrials.gov number, NCT01998971.

• Authors: Xu Steven Xu, Philippe Moreau, Saad Z Usmani, Sagar Lonial, Andrzej Jakubowiak, Albert Oriol, Amrita Krishnan, Joan Bladé, Man Luo, Yu-Nien Sun, Honghui Zhou, Ivo Nnane, William Deraedt, Ming Qi, Jon Ukropec, Pamela L Clemens
• Journal: Advances in therapy (Adv Ther) Vol. 37 Issue 4 Pg. 1464-1478 (04 2020) ISSN: 1865-8652 [Electronic] United States
• PMID: 32078124 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Oligopeptides
• daratumumab
• carfilzomib
• Lenalidomide

Topics

• Administration, Intravenous
• Adult
• Aged
• Antibodies, Monoclonal (administration & dosage, pharmacokinetics)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, pharmacokinetics)
• Drug Administration Schedule
• Female
• Humans
• Lenalidomide (administration & dosage)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy)
• Oligopeptides (administration & dosage)
• Treatment Outcome